Dr. Ghobadi on Ways of Reducing the Cost of CAR T-Cell Therapy

Armin Ghobadi, MD
Published: Wednesday, Dec 19, 2018



Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Reducing the cost of CAR T-cell therapy will depend on several factors, one of which will be the manufacturing process. One of the main drivers of cost is vector production for the transduction of T cells, says Ghobadi. That cost is most likely going to drop significantly in the coming years. When human-genome sequencing was first introduced, it cost around $3 billion to do whole-genome sequencing. Now, it can be done anywhere from $1000 to $5000.

The improvement in technology is also likely to play a role in improving vector production. As vector production gets better, the cost of production will likely be reduced. Additionally, competition is always a driver in cost reduction, explains Ghobadi. Moreover, the development of off-the-shelf CAR cells will enable physicians to make CAR T cells for many patients with 1 donor, enabling greater access and ease of production with these products.
SELECTED
LANGUAGE


Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.

Reducing the cost of CAR T-cell therapy will depend on several factors, one of which will be the manufacturing process. One of the main drivers of cost is vector production for the transduction of T cells, says Ghobadi. That cost is most likely going to drop significantly in the coming years. When human-genome sequencing was first introduced, it cost around $3 billion to do whole-genome sequencing. Now, it can be done anywhere from $1000 to $5000.

The improvement in technology is also likely to play a role in improving vector production. As vector production gets better, the cost of production will likely be reduced. Additionally, competition is always a driver in cost reduction, explains Ghobadi. Moreover, the development of off-the-shelf CAR cells will enable physicians to make CAR T cells for many patients with 1 donor, enabling greater access and ease of production with these products.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x